Winstanley, Julie (35875266800)Julie (35875266800)WinstanleyWhite, Edward (7401613169)Edward (7401613169)WhiteSaw, Robyn (6602475899)Robyn (6602475899)SawYoung, Teresa (7403038158)Teresa (7403038158)YoungBurmeister, Bryan (7004213379)Bryan (7004213379)BurmeisterNikolic, Dejan (7005493858)Dejan (7005493858)NikolicBusto-Cornide, Iria (57212170739)Iria (57212170739)Busto-CornideIglesias-Pena, Nicolás (57208689601)Nicolás (57208689601)Iglesias-PenaBoyle, Frances (59369660400)Frances (59369660400)Boyle2025-06-122025-06-122020https://doi.org/10.1002/pon.5251https://www.scopus.com/inward/record.uri?eid=2-s2.0-85076088028&doi=10.1002%2fpon.5251&partnerID=40&md5=f90550922db90be98dce50f305c11d85https://remedy.med.bg.ac.rs/handle/123456789/5078Objective: Few patient-reported outcome measures (PROMs) have been developed that adequately measure the patient-experience following diagnosis and treatment of melanoma. Building on previous research, which developed the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Module (QLQ-MEL38), the aim of this study was to further test the hypothesised domain structure and psychometric properties of the phase 3 module, in a new larger sample of melanoma patients. Methods: Melanoma patients (n = 270) were recruited from four countries (Australia, England, Serbia, and Spain). Patients completed the EORTC core questionnaire (QLQ-C30), the QLQ-MEL38, and a sociodemographic survey. Using this new larger dataset, comparisons were made with the hypothesised domain structure of the EORTC phase 3 module using principal component analysis. Items which formed subscales in a revised domain structure were then tested for goodness of fit (GoF) to the Rasch model. Results: The original hypothesised and final domain structures were similar but not identical. Twenty-four items (83%) loaded onto the same distinct subscales previously generated by phase 3, and item-by-item comparison of the two pattern matrices indicated an extremely close match. Ten items were removed from the QLQ-MEL38 phase 3 module, and rescoring of some items was required. Four subscales, together with five individual items, comprised the final instrument. Conclusion: The newly developed measure (named the Melanoma Concerns Questionnaire; MCQ-28) was found to tap into several important psychosocial domains of concern to melanoma patients, particularly those being managed in “usual” clinic settings. © 2019 John Wiley & Sons, Ltd.cancermelanomapsychometricsquality of lifereproducibility of resultssurveys and questionnaires